2. UroToday Home
  3. Trials in Progress

Trials in Progress

SPLASH Trial: Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment

Transformative Clinical Trials
Videos
Library Resources
State of the Evidence Review Articles
Written by Gina B. Carithers Editor of UroToday
August 24, 2021
In spite of the rapid progress and many exciting advances in the treatment of metastatic castration-resistant prostate cancer over the past few years, the disease remains incurable with a median overall survival of 12-35 months.1-4
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Kim Chi, MD
(UroToday.com)  There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, recently, theranostic treatment with 177Lu-PNT2002 (also known as [Lu-177]-PSMA-I&T) has demonstrated promising activity among pre-treated individuals with mCRPC. To date, 177Lu-PNT2002 has been administered to more than 300 patients in administrative reports with PSA responses of 50% or greater in 38-59% of patients.